Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of T-DM1 ± pertuzumab versus trastuzumab plus taxane in first-line HER2-positive metastatic breast cancer
jRCT2080221448Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab emtansine, pertuzumab, trastuzumab, docetaxel and paclitaxel in breast cancer (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080221448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221448.